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single [3H] thymidine-based limiting dilution analysis to determine 
HTLp and CTLp frequencies for bone marrow donor selection
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Transplantation Serology Laboratory, Transfusion Service, University Hospital Nijmegen, Nijmegen, The Netherlands
Summary: phoeyle precursor frequency assay (CTLp) can be helpful
Histocompatibility between recipient and donor is a 
critical factor in allogeneic BMT which, to a large 
extent, determines the incidence of GVHD after BMT. exists about the relevance of HTLp and CTLp frequencies 
Functional histocompatibility assays, such as the helper in donor selection. Concerning the HTLp frequency assay.
tools in addition to the standard matching procedures.
While it is generally assumed that the MLR is a poor 
predictor for the development of GVHD,1 4 no
T lymphocyte precursor frequency assay (HTLp) and 
the cytotoxic T lymphocyte precursor frequency assay 
(CTLp), have proved to be helpful tools in facilitating 
donor selection procedures. However, a major draw-
high frequencies were to correlate an increase
for the development of GVHD in unrelated donor
BMT5 and HLA-identical sibling BMT, 
not consistently found.8
<>.7 . S IS
CTLp Frequency assay
for the development of GVHD 
results are also not unequivocal.1-1
back of these assays is that they are laborious and appeared insufficiently sensitive to have a predictive value 
require large numbers of cells. We therefore adapted a in HLA-identical sibling BMT.1 In unrelated donor BMT 
[3H]thymidine-based assay, the ‘JAM’ test, as a read- high CTLp frequencies were associated with an increased 
out for CTLp frequencies, to replace the more cumber­
some 51Cr-release assay. Furthermore, we applied an 
experimental setup that enables the assessment of HTLp 
and CTLp frequencies from a single limiting dilution T cells play a role in GVHD, it is surprising that until now 
assay to reduce the number of cells needed. The newly only one group has determined both HTLp and CTLp fre­
developed assay is relatively easy to perform and has quencies in a single study.5 They concluded that both HTLp 
the advantage that different subsets of T cells can be
Although it is clear that both IL-2 secreting and cytotoxic
quantified in a single ongoing alloreaction. When the 
combined assay was applied in unrelated donor selec­
tion it proved to be a sensitive method that enables dif­
ferentiation in suitability of distinct donors for a single 
patient. Therefore, the combined HTLp/CTLp assay 
appears to be a practical and sensitive method for ident- unequivocal and mostly based on studies of small groups
and CTLp frequencies were informative, but that the advan­
tage of the HTLp assay was that it was less labour inten­
sive, more sensitive to class II mismatches, and capable of 
detecting minor antigen mismatches.
Since the data concerning the relevance of HTLp and 
CTLp frequency assays in BMT donor selection are not
ifying functional histocompatibility in related and unre­
lated donor/recipient combinations.
Keywords: helper T lymphocyte; cytotoxic T lympho-
of recipient-donor combinations, additional research is
r t o I ince of functional
cyte; analysis
In allogeneic BMT it is important to strive for histocompat-
between donor and recipient in order to reduce the
:e of GVHD after BMT. To this effect, minimal 
criteria have been established, ie serological 
at HLA-A and B-loci and molecular identity at 
DRB and DQB loci. However, a vast number of patients
assays in BMT donor selection between unrelated individ­
uals as well as within families.
A major drawback in performing these assays is that they 
are laborious and require a large number of cells to deter” 
mine both HTLp and CTLp frequencies. Furthermore, to 
study the relevance of HTLp and CTLp frequency assays 
in BMT donor selection between unrelated individuals as 
well as within families, the assays used will preferentially
to be sufficiently sensitive to detect both minor anti« 
atches and major (HLA) mismalehe
to nusnu instill develop GVHD, most likely 
minor antigens and/or as yet undetected HLA-differences. 
Functional in vitro histocompatibility assays such as the 
mixed lymphocyte reaction (MLR), helper T lymphocyte 
precursor frequency assay (HTLp), and cytotoxic T lym-
a that would
rec
e m
We
the assessment of HTLp and CTLp frequencies 
from a single limiting dilution assay (LDA), aiming at a
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adapted a | ’H|TdR-based assay, the ‘JA M ’ test,14 as a read 
out for CTLp frequencies. This relatively easy to perform 
assay served as an alternative for the more cumbersome 
5,Cr-release assay.1’ This approach led to the development 
of a complete MHJTdR-based method for determination of
both HTLp and CTLp frequencies from a single LDA.
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M aterials and methods
Cells
PBMC were isolated by density centrifugation (Lympho- 
prep; Nycoined, Oslo, Norway) either from buffy coats 
from healthy blood donors or from blood samples drawn 
from patients waiting for an allogeneic BMT, as well as 
from their genotypically HLA-identical siblings or unre­
lated donors. Cells were frozen and stored in liquid nitrogen 
until use.
HLA typing
HLA typing for HLA A, B, DR and DQ was performed
the standard microcytotoxicity assay. Additional 
oligotyping for class II using the PCR-SSO technique was 
performed in several combinations. Apparent HLA identity
BMT patients and HLA-identical sibling
donors was confirmed by defining haplotype segregation
patterns based on additional typings. For two
patients and their six potential (unrelated) donors class I 
typing was extended by using the class I SSP ARMS-PCR 
typing kit from the 12th International Histocompatibility 
Workshop (IHW). HLA-A2 subtyping was performed using 
the HLA-A*02 SSP ARMS-PCR subtyping kit from the 
12th IHW. Subtyping of B*12 was performed using a 
nested ARMS-PCR adapted from De Luca et al,15 extended 
with additional primers to increase the resolution, and 
modified to run under the conditions of the 12th IHW proto­
cols for HLA-A *02 subtyping.
pyruvate, 100 U/ml penicillin, 100 /xg/ml 
10% FCS (Gibco) and 20% supernatant of the IL-2 produc­
ing cell line MLA-144 (ATCC, TIR 201) as a source of 
IL-2, at 37°C in a humidified atmosphere containing 5% 
C 0 2. Before use the CTLL-2 cells were washed five times 
with PBS and then resuspended in culture medium without 
IL-2. The HTLp assay was performed as described by 
Schwarer et a l , 7  with minor modifications. Briefly, a limit­
ing dilution was set up as described above. On day 3, the 
plates were irradiated (40 Gy) and 1 x 103 CTLL-2 cells in 
50 /xl culture medium were added to each well. After 24 
h incubation at 37°C in a humidified atmosphere containing 
5% C 0 2, 0.5 /xCi [3H]TdR was added to each well and the 
plates were harvested the following day using a Micromate 
196 harvesting device (Canberra, Meriden, CT, USA) and 
counted in the Packard Matrix 96 Direct Beta counter 
(Canberra). A well was scored positive if the amount of 
[3H]TdR incorporation exceeded the mean plus three times 
the standard deviation of the wells containing irradiated 
stimulator cells only.
CTLp frequency assay
The CTLp assay was performed as described by Roosnek 
et al,u with minor modifications. Briefly an LDA was set 
up as described above and on days 3 and 6, fresh medium 
containing IL-2 (Proleukin) was added to a final concen­
tration of 15 U/ml. On day 10 cells were resuspended, 150 
/xl of the suspension was transferred to new plates and a 
JAM test or 5lCr-release assay was performed.
Limiting dilution assay (LDA)
Stimulation and labeling o f  the target cells
On day 5 of the LDA culture PBMC of the initial stimulator
The limiting dilution was set up in RPMI-1640 with gluta- were thawed and resuspended in culture medium sup- 
max (Gibco, Paisley, UK) supplemented with pyruvate, 100 plemented with 10 /xg/ml PHA-M (Boehringer Mannheim,
U/ml penicillin, 100 /xg/ml streptomycin (all from Gibco)
and heat-inactivated pooled human serum (PHS)
referred to as culture medium from here. Cells were thawed 
and limiting numbers of responder cells (4 x  104, 2 x  104,
1 x  104, 0.5 x 104, 0.25 x 104, 0.125 x 104, 0.06 x 104 
cells/well or 8 x l 0 4-1250 in an HLA-identical sibling
ation) were cultured in 96-well U-bottom plates 
(Greiner, Frickenhausen, Germany) with constant numbers 
(5 x 104) of irradiated (30 Gy) stimulator cells in a total 
volume of 100 /xl; 20 wells per dilution were set up. The 
following negative controls were included: irradiated stimu­
lator cells alone, effector cells alone and, effector cells 
incubated with irradiated ‘effector’ cells. Completely mis­
matched third party cells were used either as effector or in the 51Cr-release assay.
Mannheim, Germany). Cells were grown in a 24-well plates 
(Greiner, Frickenhausen, Germany) at a concentration of 
1 x 106 cells/ml. After 48 h incubation at 37°C in a humidi­
fied atmosphere containing 5% C 0 2, cells were washed and 
resuspended in medium supplemented with IL-2 (50 U/ml) 
at a concentration of 0.5 x 106 cells/ml in 24-well plates.
Target cells to be used in the 5lCr-release assay were 
then incubated at 37°C in a humidified atmosphere contain­
ing 5% C 0 2. After 2 days the cells were centrifuged (5 min 
at 500 #), the supernatant was removed and 100 ¡xC\ s 'Cr 
was added to the pellet. After 1 h incubation at 37°C the 
cells were washed five times in phosphate-buffered saline, 
resuspended in culture medium and were then ready for use
stimulator to determine stimulator capacity of the irradiated Target cells to be used in the ‘JAM’ test were incubated
stimulator cells or the responsive capacity of the effector at 37°C in a humidified atmosphere containing 5% C 0 2 for
cells, respectively. Plates were incubated at 37°C in a 
humidified atmosphere containing 5% C 0 2.
2 days of which the last 16 h were the presence of 10 /xCi 
[3H]TdR. Cells were washed once, resuspended in culture 
medium and then ready for use in the ‘JAM ’ test.
HTLp frequency assay
Chromium-release assayProliferation of the IL-2-dependent cell line CTLL-21(1 was
used as a read out for the detection of IL-2 secretion by 51Cr-labeled target cells (1 x 104 in 50 /xl) were added to
alloreactive T cells. This cell line was kept in culture con- each well of the LDA. After 4 h of incubation at 37°C in
tinuously in RPMI-1640 with glutamax, supplemented with a humidified atmosphere containing 5% C 0 2, 100 /xl of the
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combinations (Table 1). Notably, in one HLA-identical sib­
ling combination this slight decrease in sensitivity gave rise
supernatant was transferred to tubes and counted in a 
gamma counter (Wallac, Turku, Finland). A well was 
scored positive if the s,Cr-release exceeded the mean plus to a frequency that was below threshold value. Removal of 
three times the standard deviation of the wells containing the supernatant on day 3 had no influence on the outcome 
irradiated stimulator cells alone. of the CTLp assay in the combinations tested (data not
shown).
'JAM' test
•’H]TdR-labeled target cells (1 x  104 in 50 /xl) were added 
to each well of the LDA culture. After 4 h of incubation
at 37°C in a humidified i
Adaptation o f  the ‘ JAM ’ test fo r  use in a human setting
Simultaneously, we adapted the ‘JAM ’ test ([-'HfTdR reten­
tion assay) for use in a human setting to replace the more 
the wells were harvested using a Micromate 196 96-well cumbersome 5'Cr-relea.se assay as a read-out for the CTLp
device (Canberra) and counted in the Packard assay. The ‘JAM’ test, which is based on DNA tragmen-
e containing 5% C 0 2,
harvesting 
Matrix 96 Beta counter (Canberra). A f\L' tation after CTL-induced ith, was originally
i if the [-’HlTdR retention was less then the
mean minus three times the standard deviation of the wells 
containing irradiated stimulator cells alone.
developed in a mouse model and turned out to be an easier 
and more sensitive assay as compared to the standard 51
14
Combined J*H]TdR-based HTLp/CTLp frequency assay
The LDA protocol we used for generation of cytotoxic 
T lymphocytes was similar to that used in the 5 1 Cr-release- 
basecl CTLp assay as described by Roosnek et a l.11 How-
A limiting dilution was set up as described. On day 3 the ever, with respect to the target cells a prerequisite for the
plates were centrifuged (1 min 200 g) and 50 /xl of the 
supernatants was transferred to new plates and frozen at
‘JA M ’ test is that these cells are in log growth phase to 
obtain optimal [-’HlTdR incorporation. Therefore, we tested
30°C until use in the HTLp assay. Fresh medium contain- several stimulation protocols using 
ing IL-2 was added to the wells of the LDA culture to 
obtain a final concentration of 15 U/ml and this was 
repeated on day 6. On day 10, cells were resuspended, 150 
fx 1 of the suspension was transferred to new plates and a
incubation
times, cell numbers and PHA and IL-2 concentrations (data 
not shown). The protocol that appeared most optimal was 
the 5 day protocol as described in Materials and methods, 
which resulted in sufficient high levels of [-’H]TdR incor-
‘JAM’-test or 51Cr-release assay was performed as poration and low spontaneous cell death during the assay
described above. For determination of HTLp frequencies, 
the supernatants were thawed and 1 x 10-' CTLL cells in
25 /xl medium were added to the wells. After 24 h incu­
bation at 37°C in a humidified atmosphere containing 5% 
C 0 2, 0.5 /xCi [’HlTdR was added to each well and the 
wells were harvested the following day.
(<5%).
To address the question whether in our hands the ‘JAM ’ 
test was more sensitive or at least as sensitive as the 51 Cr- 
release assay, we tested several effector/stimulator combi-
Calculation o f  HTLp and CTLp frequencies
Frequency estimations were calculated using the computer 
program as developed by Strijbosch et a / .17 Frequencies 
were estimated using the jackknife version of the maximum 
likelihood analysis. Data were excluded when the goodness 
of fit was higher then 12.5 (corresponding to P values
nations (n = 9) exhibiting different degrees of HLA match, 
using both ‘JAM ’ test and s,Cr-release as a read out system. 
As shown in Table 2, the frequencies as found in the ‘JAM ’ 
and 51 Cr-release assay are not significantly different. 
Only one out of nine combinations gave a significantly 
higher frequency in the ‘JAM ’ test as compared to the 51 Cr- 
release assay, ie there is no overlap in 95% confidence 
intervals. Overall, it appears that the sensitivities of the 
‘JAM’ test and 'Cr-release assay are comparable in our 
setting, while the ‘JAM’ test is far more easy to apply.
>0.05). Statistical analysis of the data was performed using 
the Sign test.
Results
Determination o f  HTLp and  
single limiting dilution assay
frequencies from  a
Several effector/stimulator combinations were tested in the
combined assay and ared to the outcomes of the separ-
’ assays. As shown in Table 1, in 
eight out of nine combinations the HTLp frequencies were 
slightly lower when determined from supernatants as com-
pared to determined when CTLL-2 cells were added
directly to the irradiated LDA cultures. Although this slight 
decrease in sensitivity is significant according to the Sign 
test, the 95% confidence intervals overlap in six out of nine
Determination o f  HTLp and CTLp frequencies with the 
complete / ' / / ¡TdR-hased method
The final step was to combine the ‘JAM’ test and HTLp 
assay in a single assay. To validate this experimental set-up 
several combinations exhibiting multiple HLA mismatches 
were tested. Moreover, as this assay will be applied in 
donor search for unrelated as well as HLA-identical sibling 
donors, several combinations were tested that would fit 
these categories, namely HLA-identical combinations and 
combinations exhibiting only few HLA mismatches.
The data show that the assay has a broad sensitivity and 
frequencies detected range from 1:395 to 1:500 000 in the
threshold (less than 1: ID6)
there tends to be an
HTLp assay and 1:4367 to 
in the ‘JAM ’ test (Table 3). 
increase in both HTLp
in HLA antigens mismatched
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Table 1 Comparison of HTLp frequencies determined either by adding the CTLL-2 cells directly to the irradiated wells or by adding the CTLL-2 
cells to the supernaiants (combined assay)
“Number of mismatches as detected by serology,
^Number of mismatches as detected by serology for A and B-loeus and high resolution 
"’Genotypical HLA-identical sibling combination.
No. o f  mismatches HTLp 95% Cl HTLp 95% Cl
,  .  .  -  v  . fc -  1 -  1 ! 1 — I l  --------- r i  , ,  O  ■  ' « . . " • * s - r »  ’ I t s  r - - -  -  • - •  —«--------.  . « . - . w  v  * ■
(irradiated wells) (supernatants)
- -  -  ■-------------- L -  ■ — .* .■  - 1 ■ ■ w .  —«-T  * •  ■ i i  i  r r r ~  r  —  ■ ■ ■ ■ — . * - < • « .  i ^ . w .  i m . i |  ■ •>  -  -*■—  .  . .  .  — ___ 11 11 ‘ V  ~ ~ 1 1 "  ~ v ............ —
Compleielv/purtially mismatched c•ombinations
4 A/B and 2 DR mm" 1:791 547-1425 1:672 483-1109
3 A/B and 1 DR ram" 1:1100 852-1589 1:1512 1196-2079
3 A/B and 1 DR mm" 1:3448 2710-4762 1:4975 3953-6666
2 A/B and 1 DR mm" 1:1759 1388-2538 1:4830 3636-7194
2 B and I DR mm“ 1:536 396-831 1:1105 844-1602
2 B and 1 DR mm* 1:37037 27 778-55 556 1:47619 34 482-76 923
I B mmh 1:125000 17 429-500000 1:500000 2 000 000 ->  10"
1 DR rain" 1:3376 2463-5319 1:5952 4504-8772
HLA-identical sibling combination
0 mnV 1:333 333 142 857-10° Below threshold ---------------------------------
for HLA-DRB and DQB.
Table 2 Comparison of CTLp frequencies determined with either the ‘JAM' test or Cr release as a read-out for CTLp frequencies in completely
mismatched combinations (5-6 A, B, DR antigens mismatched), partially HLA-matched combinations (0-2 A, B, DR antigens mismatched), and geno­
typically HLA-identical sibling combinations
No. o f  mis matches CTLp Jam test 95% Cl CTLp Cr release 95% Cl
Completely/partially mismatched cvm binations
4 A/B and 1 DR mrir1 1:1631 1191-2593 1:6536 4854-10101
4 A/B and 2 DR mnr‘ 1:1938 1376-3279 1:1118 714-2584
4 A/B and 2 DR mm1 1:2625 1894-4274 1:2710 2016-4132
1 A locus mm1 1:11904 8261-19230 1:9346 7246-13 333
2 DR mnr1 1:7299 5263-12 048 1:7404 4504-21277
0 mml> 1:55 556 40 000-90 909 1:90 909 62 500-166 667
HLA-identical sibling combinations
0 mmc 1:90 909 52631-333 333 1:58 823 37 037-142 857
0 mm1' 1:55556 41 667-76 923 1:71428 55 556-100000
0 mmc 1:333 333 142 857-106 1:250 000 166 667-500 000
“Number of mismatches as detected by serology.
hN umber of mismatches as detected by serology for A and B-locus and high resolution oligotyping for HLA-DRB and DQB. 
"Genotypical HLA-identical sibling combination.
Table 3 HTLp and CTLp frequencies in E/S combinations exhibiting different degrees of HLA matching determined by the combined [3H]TdR 
based method“
No, o f  mismatches HTLp frequency
Completely/partially mismatched combinations
4 A/B and 1 DR mm1’ 
3 A/B and 2 DRb 
3 A/B and 2 DR"
2 A/B mmh 
I A mm and DR s 
DR subtype mmc 
DR subtype min1'
1:395 
1:1186 
1:4255 
1:8264 
1:16 666 
1:3460 
1:76 923
v & -  — — * > —'I n . 'rfu  f
5% C l
295-944 
902-1733 
3322-5952 
6289-11 905 
12 987-23 255 
2646-5000 
52 632-166 667
CTLp frequency
1:4717 
1:4367 
1:16 667 
1:9901
1:26315
1:14286 
1:200 000
95% Cl
. . . . . . .  i n  r r r - i i  r  * i *  i i h i  i -------------- I  i i i i n r ' i t i i r "  i T i ' i f c i i —  • n  -  • t i  < * * * * * * * *  k ^ .  . >•1 i. a
3425-7634 
2653-12 346 
12 821-24390 
7752-13 699 
20408-38461 
10638-21 739 
1 11 111-333 333
HLA-identical sibling combinations 
0  m m  
0 mm 
0 mm
1:500 000 
1:500000 
1:166 666
250 000-10C’
250 000 ->  10ft 
111 111-333 333
Below threshold 
1:333 333 
1:166 666
200 000- 10°
111 111-333 333
"HTLp frequencies were determined on supernatants as described in Materials and methods. The ‘JAM ’ test was used as a read-out for CTLp frequencies. 
''In effector to stimulator direction as detected by serology.
'-'In effector to stimulator direction as detected by serology for HLA-A and B and by high resolution oligotyping for HLA-DRB and DQB.
(completely mismatched vs partially/fully matched vs HLA- 
identical sibling combinations), a wide spread in fre­
quencies can be seen within each group. The CTLp 
frequencies in HLA-identical sibling combinations were 
relatively low compared to those in less well matched com­
binations, but still detectable in two out of three combi­
nations.
As in a clinical setting the HTLp and CTLp assays are 
applied to facilitate donor selection procedures, both fre­
quencies were determined in the case of two patients and 
their potential (unrelated) donors (Table 4). While all three 
potential donors for patient A were equally well matched 
for HLA using standard typing techniques, major differ­
ences in HTLp and CTLp frequencies were observed. 
Whether this was caused by unknown HLA mismatches 
and/or minor antigen mismatches is unclear at present. For 
patient B no completely HLA matched donor was available. 
Here a clear difference was observed in the CTLp fre­
quencies as measured in the case of donor 1 as compared 
to donors 2 and 3, while HTLp frequencies differ between 
all three donors. Apparently, the detected or undetected 
HLA mismatches and/or minor antigen mismatches give 
rise to different types of in vitro alloresponses in these com­
binations.
Discussion
Improvement of bone marrow donor selection procedures 
is a matter of concern since after allogeneic BMT a high 
number of patients still develop severe GVHD. In addition 
to high resolution HLA-typing techniques, functional in 
vitro histocompatibility assays, ie HTLp and CTLp fre­
quency assays, are promising methods for prediction of 
alloreactivity and the occurrence of GVHD.18 Application 
of both assays separately is laborious and requires a high 
number of patient cells.
By combining the HTLp and CTLp assays in a single 
LDA and using the ‘JAM’ test as a read out for cytotoxic­
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ity, we developed an easy and cell-saving assay which 
enables us to quantify different subsets of T cells in a single 
ongoing alloreaction. As one might expect, the nature of 
the HLA and/or minor antigens mismatched will determine 
the initial route of the alloresponse (cytokine 
production/cytotoxicity), consequently the use of two dif­
ferent read-out systems will provide more detailed infor­
mation on the in vitro histocompatibility. So far, it has been 
claimed that the CTLp assay mainly detects class I mis­
matches1 1 although class II restricted alloreactivity has been 
described.7,9 The HTLp assay has been claimed to be sensi­
tive to both HLA class I and class II mismatches as well 
as minor antigen mismatches.7 By performing a single LDA 
to obtain both frequencies more insight will emerge in the 
effect of (isolated) HLA mismatches on the initial allores­
ponse. Furthermore, the alloreactive profile of each separate 
well of the culture can be determined.
A major advantage of using the ‘JAM’ test as a read-out 
for CTLp frequencies is that it simplifies the performance 
of the CTLp assay. Handling of target cells and harvesting 
of the plates is relatively easy in this system as compared 
to others.11’19 Although the CTLp frequencies detected by 
51Cr release and ‘JAM’ test were comparable for the combi­
nations tested, it should be emphasized that the ‘JAM’ test 
is based on a different aspect of cell death as is the 51Cr- 
release assay, ie DNA fragmentation vs disruption of the 
cell membrane. Because the retention of [3H]TdR-labeIed 
DNA during the assay is very stable, longer incubation 
times can be applied, ie 6 h instead of 4, the advantage 
being that the discriminative power (scoring of positive vs 
negative wells) has increased.14
With respect to the HTLp assay two points have to be 
considered. First, as preliminary data already indicate, 
determination of HTLp frequencies, by adding the CTLL- 
2 cells to the supernatants of the LDA cultures instead of 
adding the CTLL-2 cells directly to the irradiated LDA cul­
tures, gives rise to a slight decrease in sensitivity of the 
HTLp frequency assay.20 This confirms the findings of 
Schwarer et al5 and is probably due to continued IL-2
Table 4 HTLp and CTLp frequencies in two patients and their unrelated potential donors as determined by the combined [3H]TdR-based method
HLA antigens HTLpb 95% Cl CTLpb 95% Cl
mismatched  
with the p a tie n t
Patient A
A3 A24 B18 B62 Cw*0303 Cw*0304 DRB1*1101 DRB 1*1301 DRB3*0202 DQB 1 *0603/0607 DQB1*0301
Donor 1 
Donor 2
Donor 3
Cw*0303 Cw*0700 
Cw*0303 Cw*0700 
Cw*0303 Cw*0700
1:5076 
1:58 824 
1:500 000
3774-7692 
41667-111 111 
250 000-/
1:32258 
1:200 000 
1:333 333
23 810-50000 
125 000-1 000 000 
166 667-/
Patient B
A*0201 B*1800 B*4402 Cw*0501 Cw*0700 D RBlt|!0401 DRB1*0701 DRB4*0101 DQB1*0200 DQB1*0301
Donor 1
Donor 2 
Donor 3
B *4403 B*1800 
Cw *0400 Cw*0700 
DQB 1 *0200 
D Q B1*0303/0305 
CW*0501 Cw*0501 
DRB4*0103
1:3546 2755-4975 1:10526
1:43 478 
1:17857
31 250-76 923 
13 699-25 641 1:90909
1:100000
8403-14085
58 824-1666667 
66 667-200 000
aAs detected by PCR-SSP for HLA-A, B and, Cw and high resolution oligotyping for HLA-DRB and DQB. Mismatched antigens are shown in italic 
bIn GVH direction.
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secretion after irradiation of the cultures. Whether this a complete subtyping of HLA class I and class II antigens,
phenomenon has any bearing on the functional relevance in combination with the outcome of the combined
of the lest is currently under investigation.
A second point of consideration, is the production of IL-
2 by irradiated alloreactive stimulator cells in response to 
the effector cells.-1-2- This so-called ‘back stimulation’ is
HTLp/CTLp assay and the outcome of transplantation is 
currently being performed to validate the value of the com­
bined HTLp/CTLp assay and to gain more insight into the 
functional in vitro relevance of certain HLA mismatches,
caused by alloreactive T cells in the stimulator PBMC frac- and its effect on the development of GVHD.
tion which although being irradiated, continue to produce In conclusion, the combined HTLp/CTLp assay as
IL-2. In our hands, 30 and 50 Gy irradiation doses were described here is a practical and sensitive tool for the detec- 
not always sufficient to abrogate IL-2 production in every tion of in vitro histocompatibility and can be applied in
effector-stimulator combination. This confirms the findings 
by Reisaeter el al2' who stated that irradiation doses of up 
to 100 Gy are necessary to completely abrogate the fication of mismatched HLA antigens that do not give rise
both related and unrelated patient/donor combinations. Fur­
thermore, this assay might prove to be helpful in the identi-
‘unwanted’ IL-2 production. however, to a to an alloreaction, the so-called permissible mismatches.
reduced antigen presenting capacity of the stimulator cells,
thereby affecting the outcome of both HTLp21,22 and CTLp
assays (unpublished observation). Therefore, the depletion Acknowledgements
of the IL-2 producing cells in the stimulator PBMC fraction
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is currently being evaluated in our experimental set-up. 
The HTLp and CTLp assays provide additional infor-
mation on in vitro that cannot be
deduced directly from HLA typing of patient and donor. 
Looking at two extremes with respect to HLA-matching, ie 
HLA-identical siblings on one side and completely mis­
matched unrelated combinations on the other, the HTLp 
and CTLp frequencies were always relatively low or high, 
respectively (Table 3), which is in concert with previously 
published data.5,9 However, in the group that most closely 
resembles the clinical situation of unrelated patient/donor 
combinations, ie the unrelated combinations with only few 
or no HLA mismatches, a wide spread in frequencies can 
be observed (Table 3), ranging from frequencies similar to 
those found in HLA-identical siblings up to those found in
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